Squadron Capital Management LLC — 13F Holdings & Portfolio
CIK 2050709 · latest 13F-HR filed 2026-08-14
Squadron Capital Management LLC manages $322.2M in 13F-reported U.S. long-equity assets across 43 reported positions as of its 2026-06-30 13F-HR filing. Its largest disclosed positions are RLMD (15.78%), CCCC (10.43%), COGT (10.39%). Quarter over quarter (versus its 2026-03-31 filing) the fund opened 17 new positions and exited 13; 10 existing positions rose in reported value and 4 fell.
AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.
Long-equity book
Distinct positions
Filed 2026-08-14
vs 2026-03-31
Portfolio charts
Latest quarter's book, what changed, and how the portfolio has evolved across filings.
| Name | Title / Status | Ownership | Type |
|---|
Quarter-over-quarter changes
Changes in reported position value vs the prior 13F, so price moves count too, not just shares bought or sold.
Top Adds (vs prior quarter)
- C4 THERAPEUTICS INC$27.7M +468.2%
- RELAY THERAPEUTICS INC$11.5M +171.2%
- ZENTALIS PHARMACEUTICALS INC$9.4M +111.2%
- INVENTIVA SA$6.2M +210.0%
- KODIAK SCIENCES INC$5.0M +34.5%
Top Trims
- RELMADA THERAPEUTICS INC-$8.1M -13.8%
- NEXTCURE INC-$2.7M -96.4%
- LIPOCINE INC NEW-$1.5M -42.3%
- PASITHEA THERAPEUTICS CORP-$1.0M -66.9%
New Positions
- ENLIVEN THERAPEUTICS INC$8.1M
- ADAGENE INC$5.2M
- FORTE BIOSCIENCES INC$4.8M
- INFLARX NV$4.5M
- ASSEMBLY BIOSCIENCES INC$4.4M
Exited Positions
- KALVISTA PHARMACEUTICALS INC$19.8M
- ABIVAX SA$14.5M
- NEKTAR THERAPEUTICS$9.0M
- SCYNEXIS INC$7.0M
- EUPRAXIA PHARMACEUTICALS INC$4.9M
Squadron Capital Management LLC Holdings (2026-06-30)
Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).
| # | Issuer | Symbol | CUSIP | Value | Weight | Shares | Type |
|---|---|---|---|---|---|---|---|
| 1 | RELMADA THERAPEUTICS INC | RLMD | 75955J402 | $50.9M | 15.78% | 7,350,000 | SH |
| 2 | C4 THERAPEUTICS INC | CCCC | 12529R107 | $33.6M | 10.43% | 7,200,000 | SH |
| 3 | COGENT BIOSCIENCES INC | COGT | 19240Q201 | $33.5M | 10.39% | 865,000 | SH |
| 4 | KODIAK SCIENCES INC | KOD | 50015M109 | $19.5M | 6.05% | 500,000 | SH |
| 5 | RELAY THERAPEUTICS INC | RLAY | 75943R102 | $18.1M | 5.63% | 970,000 | SH |
| 6 | ZENTALIS PHARMACEUTICALS INC | ZNTL | 98943L107 | $17.9M | 5.57% | 3,700,000 | SH |
| 7 | EDGEWISE THERAPEUTICS INC | EWTX | 28036F105 | $11.8M | 3.66% | 290,000 | SH |
| 8 | MAZE THERAPEUTICS INC | MAZE | 578784100 | $10.0M | 3.10% | 335,000 | SH |
| 9 | INVENTIVA SA | IVA | 46124U107 | $9.2M | 2.86% | 2,435,000 | SH |
| 10 | ADLAI NORTYE LTD | ANL | 00704R109 | $8.8M | 2.73% | 764,876 | SH |
| 11 | ENLIVEN THERAPEUTICS INC | ELVN | 29337E102 | $8.1M | 2.52% | 160,000 | SH |
| 12 | ARRIVENT BIOPHARMA INC Call | AVBP | 04272N102 | $6.4M | 1.97% | 183,000 | SH |
| 13 | PALISADE BIO INC | PALI | 696389402 | $6.3M | 1.95% | 3,000,000 | SH |
| 14 | BIOAGE LABS INC Call | BIOA | 09077V100 | $6.1M | 1.90% | 250,000 | SH |
| 15 | INHIBIKASE THERAPEUTICS INC | IKT | 45719W205 | $6.1M | 1.89% | 3,000,000 | SH |
| 16 | ADAGENE INC | ADAG | 005329107 | $5.2M | 1.63% | 1,250,000 | SH |
| 17 | FORTE BIOSCIENCES INC | FBRX | 34962G208 | $4.8M | 1.48% | 225,000 | SH |
| 18 | REZOLUTE INC Call | RZLT | 76200L309 | $4.7M | 1.45% | 900,000 | SH |
| 19 | INFLARX NV | IFRX | N44821101 | $4.5M | 1.39% | 2,000,000 | SH |
| 20 | ASSEMBLY BIOSCIENCES INC | ASMB | 045396207 | $4.4M | 1.36% | 160,000 | SH |
| 21 | COMPASS PATHWAYS PLC Call | CMPS | 20451W101 | $4.3M | 1.34% | 305,000 | SH |
| 22 | PROMIS NEUROSCIENCES INC | PMN | 74346M505 | $4.3M | 1.33% | 324,977 | SH |
| 23 | CONTINEUM THERAPEUTICS INC | CTNM | 21217B100 | $4.3M | 1.32% | 260,000 | SH |
| 24 | COMPASS PATHWAYS PLC | CMPS | 20451W101 | $4.2M | 1.32% | 300,000 | SH |
| 25 | DEFINIUM THERAPEUTICS INC | DFTX | 24477V105 | $4.0M | 1.24% | 85,000 | SH |
| 26 | SOL-GEL TECHNOLOGIES LTD | SLGL | M8694L137 | $3.9M | 1.20% | 52,000 | SH |
| 27 | BIOAGE LABS INC | BIOA | 09077V100 | $3.8M | 1.18% | 155,000 | SH |
| 28 | SCYNEXIS INC | SCYX | 811292309 | $3.1M | 0.96% | 756,884 | SH |
| 29 | PROQR THRAPEUTICS N V | PRQR | N71542109 | $2.8M | 0.87% | 1,511,496 | SH |
| 30 | DISC MEDICINE INC Call | IRON | 254604101 | $2.2M | 0.68% | 30,000 | SH |
| 31 | REZOLUTE INC | RZLT | 76200L309 | $2.1M | 0.65% | 403,410 | SH |
| 32 | LIPOCINE INC NEW | LPCN | 53630X203 | $2.1M | 0.64% | 810,000 | SH |
| 33 | ZENTALIS PHARMACEUTICALS INC Call | ZNTL | 98943L107 | $2.1M | 0.64% | 426,000 | SH |
| 34 | C4 THERAPEUTICS INC Call | CCCC | 12529R107 | $1.9M | 0.58% | 400,000 | SH |
| 35 | ULTRAGENYX PHARMACEUTICAL IN Call | RARE | 90400D108 | $1.8M | 0.57% | 55,000 | SH |
| 36 | CUE BIOPHARMA INC | CUE | 22978P205 | $1.6M | 0.49% | 50,000 | SH |
| 37 | CALCIMEDICA INC | CALC | 38942Q202 | $1.3M | 0.40% | 1,244,864 | SH |
| 38 | QUINCE THERAPEUTICS INC | QNCX | 22053A305 | $734.4K | 0.23% | 40,375 | SH |
| 39 | NUVECTIS PHARMA INC Call | NVCT | 67080T108 | $711.7K | 0.22% | 38,700 | SH |
| 40 | PASITHEA THERAPEUTICS CORP | KTTA | 70261F202 | $515.4K | 0.16% | 1,000,000 | SH |
| 41 | INMED PHARMACEUTICALS INC | INM | 457637700 | $503.8K | 0.16% | 325,000 | SH |
| 42 | NEUMORA THERAPEUTICS INC. | NMRA | 640979100 | $170.0K | 0.05% | 100,000 | SH |
| 43 | NEXTCURE INC | NXTC | 65343E207 | $103.1K | 0.03% | 64,464 | SH |
| Period | Filed | AUM | Holdings | Accession |
|---|---|---|---|---|
| 2026-06-30 | 2026-08-14 | $322.2M | 43 | 0002050709-26-000027 |
| 2026-03-31 | 2026-05-15 | $272.9M | 37 | 0002050709-26-000017 |
| 2025-12-31 | 2026-02-17 | $236.0M | 33 | 0002050709-26-000010 |
SUITE 1008
OAK BROOK, IL 60523